SEATTLE and RICHMOND, BRITISH COLUMBIA - August 26, 2026 - Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. This partnership allows SignalChem Biotech to incorporate these AI-designed technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use.
The significance of this agreement lies in its potential to accelerate drug discovery and life science research by providing researchers with access to advanced, AI-engineered tools. By integrating LuxSit luciferase and NovoBodies into SignalChem’s custom assay platform, the collaboration aims to help researchers obtain high-quality discovery candidates more rapidly. Dr. Rob Burgess, Chief Business Officer of Sino Biological, emphasized that this agreement strengthens their ability to address complex biological questions and advance research programs more efficiently.
LuxSit is an AI-designed luciferase engineered for robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies offer versatile tools for developing customized assays and discovery workflows. Daniel Silva Manzano, PhD, CEO of Monod Bio, noted that SignalChem Biotech and Sino Biological have the scientific expertise, customer reach, and service infrastructure to bring these technologies to a broad customer base, expanding the reach of Monod Bio’s platform and reinforcing the value of its Monod Inside model.
This licensing agreement is part of Sino Biological’s broader strategy to incorporate AI-enabled technologies across its global life science tools and services portfolio. SignalChem Biotech, a wholly-owned subsidiary of Sino Biological, provides specialized reagents and CRO services supporting drug discovery and life science research. The collaboration enhances SignalChem’s specialized CRO capabilities, offering researchers new options for custom assay development.
The deal also highlights the growing trend of integrating AI-designed proteins into commercial products and services. Monod Bio uses AI-powered de novo protein design to create novel binders, biosensors, and other functional proteins for research and diagnostic applications. Through its Monod Inside model, the company partners with life science companies to integrate its technologies into next-generation products and services.
While the financial impact of this agreement is not expected to be material for Sino Biological due to its broad product portfolio, the strategic value lies in expanding its service offerings and staying at the forefront of technological innovation. For more information about Sino Biological and SignalChem Biotech, visit Sino Biological. For details on Monod Bio, visit Monod Bio.
